<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530981</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-2618-01-007</org_study_id>
    <nct_id>NCT04530981</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST</brief_title>
  <official_title>A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration for Repaglinide</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.</time_frame>
    <description>Measure the Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) from time 0 up to time t (AUC0-t) for Repaglinide</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.</time_frame>
    <description>Measure the AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 and extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.</time_frame>
    <description>Measure the AUC0-∞</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Cycle 1 through study completion (~ 12 months). Each cycle is 28 days.</time_frame>
    <description>Adverse events [TEAEs, SAEs, AESIs], dose reduction, dose interruption, or discontinuation, vital signs (heart rate [beats/min], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>GIST - Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Repaglinide 0.5 mg + Ripretinib 150 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ripretinib</intervention_name>
    <description>Oral KIT/PDGFRA kinase inhibitor</description>
    <arm_group_label>Repaglinide 0.5 mg + Ripretinib 150 mg QD</arm_group_label>
    <other_name>QINLOCK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Oral antihyperglycemic agent</description>
    <arm_group_label>Repaglinide 0.5 mg + Ripretinib 150 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥18 years of age.&#xD;
&#xD;
          2. Patients must have a histologic diagnosis of GIST.&#xD;
&#xD;
          3. Patients must have GIST that has progressed on or have intolerance to at least 2 lines&#xD;
             of prior TKI therapies.&#xD;
&#xD;
          4. Patients must have an Eastern Cooperative Oncology Group performance score of ≤ 2.&#xD;
&#xD;
          5. If a female of childbearing potential, must have a negative pregnancy test prior to&#xD;
             enrollment and agree to follow the contraception requirements.&#xD;
&#xD;
          6. Adequate organ and bone marrow function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior anticancer or other investigational therapy within 28 days or 5× the&#xD;
             half-life prior to the first dose.&#xD;
&#xD;
          2. Prior treatment with ripretinib.&#xD;
&#xD;
          3. Patients who have had prior repaglinide treatment within 30 days of screening.&#xD;
&#xD;
          4. History or presence of clinically relevant cardiovascular abnormalities.&#xD;
&#xD;
          5. Gastrointestinal abnormalities including but not limited to:&#xD;
&#xD;
               -  inability to take oral medication,&#xD;
&#xD;
               -  malabsorption syndromes,&#xD;
&#xD;
               -  requirement for intravenous alimentation.&#xD;
&#xD;
          6. Patients who have type 1 or type 2 diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>785-830-2100</phone>
    <email>clinicaltrials@deciphera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Attia, DO, CCRP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Z D'Amato, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

